12 recruiting, 9 completed, 6 not yet recruiting, 4 active not recruiting. 34 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Recruiting 12, Completed 9, Not yet recruiting 6, Active not recruiting 4, Suspended 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Recruiting 2, Suspended 1 |
| Phase 3 | 2 | Not yet recruiting 2 |
Follow luspatercept: new trials by email Literature Review of luspatercept trials Research Report on luspatercept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Emavusertib - Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 270 | 2026-12-18 | 2026-09-22 |
| Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia Luspatercept, Pacritinib - Myelofibrosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 50 | 2026-12-01 | 2026-11-13 |
| Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia Gecacitinib, Luspatercept - Myelofibrosis | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 31 | 2026-11-01 | 2026-11-16 |
| A Study of Luspatercept in People With Anemia Luspatercept - Anemia, Chronic Kidney Disease | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2026-07-20 | 2026-10-13 |
| Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies Luspatercept, Epoetin - Luspatercept, Epoetin | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 90 | 2026-06-15 | 2026-06-09 |
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| Luspatercept in Patients Affected With Rare Inherited Anemias Reblozyl - Hereditary Red Blood Cell Disorder (Disorder) | Phase 2 | Recruiting | EuroBloodNet Association | 45 | 2026-03-17 | 2026-11-17 |
| The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT Luspatercept - HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-03-14 | 2026-03-04 |
| Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients Luspatercept combined with low-dose thalidomide, Luspatercept plus placebo - Transfusion-dependent β-thalassemia Patients | Phase 2 | Recruiting | Rongrong Liu | 78 | 2026-02-01 | 2026-01-13 |
| Luspatercept + Darbepoetin in MDS Luspatercept, Darbeopoetin - MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Yale University | 60 | 2025-12-16 | 2026-09-14 |
| Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) Luspatercept - Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 46 | 2025-10-01 | 2026-01-23 |
| Luspatercept for Clonal Cytopenias of Uncertain Significance Luspatercept - CCUS Clonal Cytopenia of Undetermined Significance, Anemia | Phase 2 | Recruiting | Weill Medical College of Cornell University | 50 | 2025-03-25 | 2026-03-24 |
| Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis Momelotinib, Luspatercept - Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Recruiting | GlaxoSmithKline | 68 | 2025-02-28 | 2026-11-04 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-11-02 |
| A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) Luspatercept - Myelodysplastic Syndromes | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2024-03-01 | 2026-06-22 |
| The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes Luspatercept - Lower Risk MDS Per IPSS-R | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 36 | 2023-07-01 | 2024-03-12 |
| Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms Luspatercept - Myelodysplastic Syndromes, Myeloproliferative Neoplasm | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2023-02-21 | 2026-05-05 |
| Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | Phase 2 | Terminated | Mayo Clinic | 3 | 2023-02-20 | 2024-09-19 |
| Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia Luspatercept, Cyclosporine - Aplastic Anemia | Phase 2 | Completed | Bing Han | 58 | 2022-12-19 | 2025-09-16 |
| A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia Luspatercept, Placebo - Anemia | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 189 | 2022-12-09 | 2026-09-10 |
Showing 20 of 34. Sign in to see all of them.
Myelodysplastic Syndromes (12) · Anemia (11) · Primary Myelofibrosis (5) · beta-Thalassemia (4) · Myeloproliferative Disorders (3) · Hematologic Neoplasms (2) · Thrombocytopenia (2) · Anemia, Aplastic (1) · Anemia, Refractory, with Excess of Blasts (1) · Leukemia, Myeloid, Acute (1) · Leukopenia (1) · Neutropenia (1) · Renal Insufficiency, Chronic (1) · Thalassemia (1) · Thrombocytosis (1)
Celgene (5) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (4) · Bristol-Myers Squibb (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Nanfang Hospital, Southern Medical University (2) · National Cancer Institute (NCI) (2) · Associazione Qol-one (1) · Bing Han (1) · Case Comprehensive Cancer Center (1) · EuroBloodNet Association (1) · GlaxoSmithKline (1) · Groupe Francophone des Myelodysplasies (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
United States (13) · China (10) · Italy (10) · Germany (5) · Greece (5) · France (4) · Thailand (3) · Canada (2) · Japan (2) · Lebanon (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Hong Kong (1) · India (1) · Malaysia (1)
Qifa Liu (2) · Abhishek A. Mangaonkar, M.B.B.S. (1) · Akriti Jain, MD, FACP (1) · Anne Sophie Kubasch, Dr. (1) · Guillermo Garcia-Manero, M D (1) · Jeevan Shetty, MD (1) · Jerald P Radich (1) · Maximilian Stahl, MD (1) · Mikkael Sekeres, MD (1) · Pinkal Desai, MD (1) · Rami Komrokji, MD (1) · Rena J Buckstein (1)
PMID 28870615, PMID 30617198, PMID 35998303, PMID 36505885, PMID 20424252, PMID 28096091, PMID 29895954, PMID 33570654, PMID 34002031, PMID 36007538, PMID 36902217, PMID 36948565, PMID 37311468, PMID 37345627, PMID 37606495, PMID 37704579, PMID 38820422, PMID 39991012, PMID 40875596, PMID 41857682, PMID 42057135
2014 (2), 2015 (1), 2017 (1), U10CA180863 (1), U10CA180888 (1)